✦ LIBER ✦

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma

✍ Scribed by Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P. de Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Robert Ilaria Jr, M. L. Keohan

Book ID: 118299109
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 155 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9819-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of tasisulam sodium (LY5

A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma

✍ John M. Kirkwood; Rene Gonzalez; Douglas Reintgen; Philip R. Clingan; Robert R. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

Phase II Trial of Pyrazoloacridine as Se

Phase II Trial of Pyrazoloacridine as Second-Line Therapy for Patients with Unresectable or Metastatic Transitional Cell Carcinoma

✍ Paul M. Dodd; John A. McCaffrey; Madhu Mazumdar; Evelyn Icasiano; Geralyn Higgin 📂 Article 📅 2000 🏛 Springer US 🌐 English ⚖ 50 KB

First-line treatment of metastatic or lo

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study

✍ George D. Demetri; Axel Le Cesne; Sant P. Chawla; Thomas Brodowicz; Robert G. Ma 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 818 KB

194 A Phase II Study of Trastuzumab Plus

194 A Phase II Study of Trastuzumab Plus Capecitabine with or Without Pertuzumab for HER2-positive Metastatic Breast Cancer as Second-line Treatment (PHEREXA)

✍ A. Urruticoechea; P. Canney; R. Separovic; T. Bachelot; J. Efran; J.L. Canon; P. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

815 Elderly patients (pts) with unresect

815 Elderly patients (pts) with unresectable localised or metastatic non-small-cell-lung-cancer (NSCLC): results of a phase II study with oral navelbineâ (nvb) given as a weekly monotherapy and first line treatment

✍ U. Gatzemeier; F. De Marinis; C. Manegold; P. Mali; L. Portalone; O. Castelnau; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 336 KB

277 ORAL Interim results of a phase II r

277 ORAL Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 142 KB